SCHEMBL12706248

SCHEMBL12706248

BC(C)=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31115 0.72
SCHEMBL17616038 0.72
Water SCHEMBL11805223 0.67
SCHEMBL8948 0.67
SCHEMBL7893123 0.67
SCHEMBL1275690 0.67
SCHEMBL13591500 0.67
SCHEMBL1425834 0.67
SCHEMBL5861030 0.67 FFAR3 (0.40)
SCHEMBL23572290 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1022 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2024-07-18 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230287001-A1 Organic Semiconducting Compounds RAYNERGY TEK INC (TW) 2023-09-14 US disclosed
EP-3835290-B1 OXADIAZOLINE COMPOUND OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND USE METHOD THEREFOR NIHON NOHYAKU CO LTD (JP) 2023-09-06 EP disclosed
US-20230202977-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. 2023-06-29 US disclosed
US-20230183254-A1 METHOD OF MAKING SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-06-15 US disclosed
EP-4194438-A1 ACETAL-BASED COMPOUND, ACETAL-BASED PREPOLYMER, ACETAL-BASED POLYMER, AND PHOTORESIST COMPOSITION COMPRISING THE SAME Samsung Electronics Co., Ltd. (KR) 2023-06-14 EP disclosed
US-11674162-B2 Selective advantage in fermentation GINKGO BIOWORKS, INC. (US) 2023-06-13 US disclosed
US-20230121730-A1 OXADIAZOLINE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME NIHON NOHYAKU CO., LTD. (JP) 2023-04-20 US disclosed
US-20230032098-A1 ENCAPSULATED PRO-PERFUME COMPOUNDS FIRMENICH SA (CH) 2023-02-02 US disclosed
EP-1745784-A1 Oxazolidinone derivatives and use thereof as antibiotics FERRER INTERNACIONAL, S.A. (ES) 2007-01-24 EP disclosed
US-7166588-B2 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2007-01-23 US disclosed
US-7166588-B2 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2007-01-23 US disclosed
US-20070004872-A1 suitable for encapsulating solid state devices includes an epoxy resin( examples bisphenol A or F epoxy resin, phenol or cresol novolak resins etc.) a hardener, a poly(arylene ether) resin and sililca filler; curable; exhibits improved increased copper substrte adhesion and reduced shrinkage CITIBANK, N.A., AS COLLATERAL AGENT 2007-01-04 US disclosed
US-20070004871-A1 Curable composition and method CITIBANK, N.A., AS COLLATERAL AGENT 2007-01-04 US disclosed
US-20070004819-A1 A curable epoxy resin , two latent cationic curing catalyst, a free radical-producng cocatalyst and inorganic filler of about 70-95 weight % based on the total weight; catalyst allows the use of increased filler loadingsto reduce moisture absorption and thermal expansion; encapsulating solid state device CITIBANK, N.A., AS COLLATERAL AGENT 2007-01-04 US disclosed
WO-2007000432-A1 OXAZOLIDINONE DERIVATIVES AND USE THEREOF AS ANTIBIOTICS FERRER INTERNACIONAL, S. A. (ES) 2007-01-04 WO disclosed
US-20070004904-A1 G-CSF CONJUGATES MAXYGEN HOLDINGS, LTD. 2007-01-04 US disclosed
WO-2005087235-A1 PYRROLIDINE COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTES (CN) 2005-09-22 WO disclosed
WO-2003034989-A2 α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE ENANTA PHARMACEUTICALS, INC. (US) 2003-05-01 WO disclosed